How can bruxism cause headaches? Bruxism causes morning, tension, and migraine headaches via jaw muscle fatigue and trigeminal sensitization. Learn the types, triggers, and relief options.
Written by Ann C. McCulloch, MBA | Medically Reviewed by Bradley Allen Eli, DMD, MS
Botox (botulinum toxin type A) is a clinically recognized treatment option for TMJ pain of muscular origin, working by temporarily reducing the contraction of overactive jaw muscles and interrupting the neurobiological cycle that sustains chronic pain. When conservative treatments have not provided adequate relief, Botox injections into the masticatory muscles — primarily the masseter and temporalis — can meaningfully reduce pain intensity and improve jaw function. For best results, Botox should be combined with a multimodal approach to jaw pain management during its approximately 90-day window of effect.
Botox is a neurotoxic protein produced by Clostridium botulinum bacteria. While its origins may sound alarming, its medical applications have expanded substantially over the past three decades. Its primary mechanism is to prevent the release of acetylcholine at the neuromuscular junction, effectively stopping muscle contraction. For chronic pain conditions driven by persistent muscle tension — like many forms of TMJ disorder — this is a powerful intervention. Chronic jaw muscle tension produces a cascade of harmful local effects: inflammation, muscle fatigue, and poor oxygenation of the affected tissue, all of which amplify pain signals.
But Botox has a second, equally important mechanism that is independent of its muscle-relaxing effect: it modulates the neurobiological processes that sustain chronic pain. To understand this, it helps to understand how chronic pain perpetuates itself through a bidirectional cycle between the peripheral nervous system and the brain’s pain-processing centers. (For more on why some jaw pain resolves quickly while other cases become chronic, see how long does TMJ pain last.)
Peripheral sensitization occurs when sensory neurons amplify the pain signals they send to the brain. In the acute setting, this is largely driven by inflammation — think of how a minor brush against injured skin can feel intensely painful. In chronic pain states, the neurotransmitter receptors on sensory nerves become upregulated, meaning the pain system is running at a higher gain than normal even without active tissue injury.
Central sensitization is characterized by increased responsiveness of pain neurons in the central nervous system. The clinical result is hypersensitivity, the perception of pain in response to normally non-painful stimuli (allodynia), and an expansion of the pain field beyond the original site of injury.
These two processes reinforce each other in a self-sustaining cycle:
This vicious cycle of bidirectional reinforcement is the neurobiological basis for chronic TMJ pain. A 2026 review published in Toxins by researchers at Harvard Medical School, Johns Hopkins, and the Danish Headache Center specifically examined how Botox addresses both peripheral and central sensitization in the context of temporomandibular disorders — providing a compelling mechanistic framework for its use beyond simple muscle relaxation.
By causing a partial, temporary reduction in masticatory muscle contractility, Botox significantly decreases jaw muscle tension and breaks the chronic pain cycle. This effect is considerably more powerful than that of muscle relaxants or other pharmacologic therapies alone. Botox also directly reduces neurotransmitter release from peripheral sensory neurons, decreasing peripheral sensitization. Evidence from preclinical models has shown that when Botox is injected on one side of the body, both sides can experience pain reduction — suggesting a systemic effect on central sensitization that goes beyond local muscle action.
While there are over 30 recognized subtypes of temporomandibular disorders (TMDs), a significant subset are driven primarily by jaw muscle tension rather than structural derangement or degeneration of the joint itself. Botox research in this area has concentrated on these muscle-dominant presentations, particularly myofascial pain of the masticatory muscles.
Multiple randomized controlled trials and systematic reviews have now confirmed that Botox is an effective treatment for chronic TMJ pain of muscular origin. A 2024 systematic review and meta-analysis published in Annals of Medicine and Surgery, examining 20 randomized controlled trials, concluded that BTX-A injection is more effective than placebo for relieving myofascial pain in TMD patients, and recommended low-dose protocols for those who have not achieved adequate relief from conservative treatments. An additional 2023 randomized, double-blind, placebo-controlled pilot study — the first of its kind to evaluate TMD muscular pain and associated headaches simultaneously — found that Botox injections into the masseter, temporalis, and cervical muscles produced significant reductions in orofacial pain intensity, headache severity, and the number of active muscle tender points over a 12-week follow-up period.
Outcomes across studies consistently include reduction in self-reported pain levels, decreased frequency of pain medication use, and in some studies, meaningful improvements in jaw range of motion. Understanding these outcomes is important in the context of what triggers and perpetuates TMJ disorders in the first place.
The connection between jaw muscle tension and headaches is particularly relevant here. Tension-type and migraine headaches are closely associated with masticatory muscle dysfunction, and “headache associated with TMD” is recognized as its own diagnostic category within the formal classification criteria for temporomandibular disorders.
“Numerous studies have documented the effectiveness of Botox for headaches. Interestingly, one of the main injection sites for treating both migraine and tension headaches is the temporalis muscle, a primary TMJ muscle. Orofacial pain specialists have appreciated the close association between headaches and jaw muscle tension for years,” explains Bradley Eli, DMD, MS, a specialist in TMJ disorders.
Patients who also experience bruxism-related headaches alongside jaw pain may find that Botox addresses both symptom clusters simultaneously, given the overlap in target muscles. This is also relevant for patients whose jaw clenching has a psychogenic component — the relationship between anxiety and jaw clenching is well established and can perpetuate the same muscle-tension cycle that Botox is designed to interrupt.
Because most orofacial pain specialists use low doses in their treatment protocols, side effects and complications are uncommon. The following are potential adverse effects that can occur with Botox injections for TMJ pain:
The effect of Botox on masticatory muscles typically lasts approximately 90 days. This therapeutic window is a critical opportunity — not simply a passive period of pain relief, but an active window in which the nervous system is less reactive and the muscles are more amenable to rehabilitation. This is the ideal time to implement a comprehensive, multimodal strategy for jaw pain relief.
The evidence strongly supports a multimodal approach rather than Botox alone. Strategies to pursue during the 90-day window include:
All of these components are included in the Speed2Treat® Home Healing Kit. This includes the QuickSplint® anterior bite guard, a neoprene jaw wrap with reusable hot/cold packs, jaw exercise instructions, self-guided behavioral therapy techniques for pain management, and more. If you are planning on getting Botox for TMJ pain, consider using the Home Healing Kit to improve your chances of a successful outcome.
If you are considering Botox as a treatment for your TMJ disorder, bringing the right questions to your appointment can help you make a more informed decision and set realistic expectations:
Botox is not currently FDA-approved specifically for TMJ disorders or jaw pain. It is used off-label for this indication by orofacial pain specialists and oral surgeons. It does carry FDA approval for other pain-related indications, including chronic migraine and cervical dystonia, and there is a substantial and growing body of clinical evidence supporting its use for myofascial TMD pain when conservative treatments have failed.
Most patients begin to notice a reduction in jaw muscle tension and pain within 5 to 10 days of injection, with peak effect typically reached at around two to four weeks. The full therapeutic benefit — including any effect on associated headache frequency — may take up to four weeks to become apparent. The pain-relieving effect generally lasts approximately 90 days, at which point repeat injections may be considered.
Dosing varies by provider and patient anatomy, but most orofacial pain specialists use relatively low doses — typically in the range of 25 to 50 units per masseter muscle and 15 to 25 units per temporalis muscle, for a total of approximately 100 to 200 units per session. Low-dose protocols are preferred because they reduce the risk of side effects such as difficulty chewing and facial muscle atrophy while still providing meaningful pain relief.
Yes. By reducing the force-generating capacity of the masseter and temporalis muscles, Botox can significantly decrease the intensity of jaw clenching and teeth grinding. This is particularly relevant for patients whose bruxism is contributing to TMJ pain, headaches, or tooth wear. However, Botox does not eliminate the underlying neurological drive to clench; behavioral therapy and an intraoral splint remain important adjuncts to address the root cause.
At the low doses used for TMJ treatment, cosmetic changes are uncommon after a single course of treatment. However, with repeated injections over time, some patients experience mild reduction in masseter muscle bulk, which can subtly slim the lower face. In rare cases, inadvertent spread of the toxin to adjacent muscles can cause temporary drooping of the eyelid or brow, or asymmetry of the smile. These effects are reversible as the Botox wears off.
These are not competing treatments — they address different aspects of the condition. An intraoral splint or mouth guard for TMJ pain protects teeth, offloads the joint, and can reduce nocturnal clenching force. Botox reduces the muscle’s contractile force directly and modulates pain sensitization. For patients with moderate to severe myofascial TMJ pain, the combination of Botox and a well-fitted splint during the 90-day window typically produces better outcomes than either treatment alone.
